Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled Trial
Although the combination of TACE and sorafenib did not demonstrate a significant improvement in OS in the ITT analysis, it met the secondary endpoints, including TTP and post hoc PFS. These findings provide valuable insights for the design of future trials and highlight the importance of integrating locoregional interventions with systemic therapies in the management of advanced-stage HCC.
Authors
- Nan You
- Ming Huang (ORCID: https://orcid.org/0000-0002-4623-0114)
- Jianbing Wu (ORCID: https://orcid.org/0000-0002-4576-7286)
- Jing Li (ORCID: https://orcid.org/0009-0004-4919-320X)
- Haiping Li
- Yan Zhao (ORCID: https://orcid.org/0000-0002-6148-5908)
- Weijie Mu (ORCID: https://orcid.org/0000-0002-5644-1142)
- Lin Zheng
- Yong Lv (ORCID: https://orcid.org/0000-0003-2745-3432)
- Guohong Han (ORCID: https://orcid.org/0000-0003-4568-3776)
- Dongdong Xia (ORCID: https://orcid.org/0000-0001-8664-2984)
- Wengang Guo (ORCID: https://orcid.org/0000-0001-8887-9352)
- Zhenyu Wang (ORCID: https://orcid.org/0000-0002-5114-435X)
- Lei Li (ORCID: https://orcid.org/0000-0001-5478-5681)
- Wei Bai (ORCID: https://orcid.org/0000-0002-1298-8787)
- Daiming Fan (ORCID: https://orcid.org/0000-0002-2466-5002)
- Weixin Ren
- Diwen Zhu
- Rong Ding (ORCID: https://orcid.org/0000-0003-2714-2511)
- Wukui Huang (ORCID: https://orcid.org/0000-0002-8022-7242)
- Yongjin Zhang (ORCID: https://orcid.org/0000-0002-8979-8826)
- Hui Zhang (ORCID: https://orcid.org/0000-0002-8142-8142)
- Zhanxin Yin (ORCID: https://orcid.org/0000-0003-4346-7551)
- Jie Yuan (ORCID: https://orcid.org/0000-0002-3604-6874)
- Xiaomei Li (ORCID: https://orcid.org/0000-0001-6505-3363)
- Peng Zhang
- Bohan Luo
Institutions
- Central South University (CN)
- Nanchang University (CN)
- Army Medical University (CN)
- Xinjiang Medical University (CN)
- Kunming Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
- Qinghai University Affiliated Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Tumor Hospital of Xinjiang Medical University (CN)
- Medical Center Hospital (US)
- Second Affiliated Hospital of Nanchang University (CN)
- Xinqiao Hospital (CN)
- Xi’an International University (CN)
- Southwest Hospital (CN)
- Henan Cancer Hospital (CN)
- Hunan Provincial People's Hospital (CN)
- Xiangya Hospital Central South University (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1159/000546530
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Bayer HealthCare
- National Natural Science Foundation of China